Blog

30 June 2016 - The Pan Canadian Expert Review Committee has issued a final recommendation on the use of cobimetinib ...

3 June 2016 - Final recommendation is conditional on cost-effectivness being improved to an acceptable level. ...

26 May 2016 - CADTH is engaging with the pan-Canadian Pharmaceutical Alliance office (pCPA), and effective immediately will be including the ...

7 January 2016 - The ERC has recommended the funding of ruxolitinib phosphate (Jakavi) so long as its cost-effectiveness is ...

3 December 2015 - The recommendation is for the use of lenalidomide in combination with low-dose dexamethasone for treatment of ...

3 December 2015 - The ERC has recommended the use of panitumumab in combination with FOLFOX for the first-line treatment of ...

3 December 2015 - The Committee was not confident of the net clinical benefit due to the limitations of the ...

[:content [\T \h \e \space \U \K \space \N \H \S \space \i \s \space \t \o \space \b \e \space \a \d \v \i \s \e \d \space \t \h \a \t \space \i \t \space \s \h \o \u \l \d \n \' \t \space \r \o \u \t \i \n \e \l \y \space \p \r \o \v \i \d \e \space \p \e \r \t \u \z \u \m \a \b \space \( \P \e \r \j \e \t \a \) \space \a \s \space \a \space \t \r \e \a \t \m \e \n \t \space \f \o \r \space \c \e \r \t \a \i \n \space \p \a \t \i \e \n \t \s " ..."]]

[:content [\T \h \e \space \p \C \O \D \R \space \E \x \p \e \r \t \space \R \e \v \i \e \w \space \C \o \m \m \i \t \t \e \e \space \( \p \E \R \C \) \space \h \a \s \space \r \e \c \o \m \m \e \n \d \e \d \space \t \h \e \  \f \u \n \d \i \n \g \space \o \f \space \R \e \v \l \i \m \i \d \space \( \l \e \n \a \l \i \d \o \m \i \d \e \) \  \a \s \space \a \space \m \a \i \n \t \e \n \a \n \c \e \space \t \r \e \a \t \m \e \n \t \space \f \o \r \space \p \a \t \i \e \n \t \s \space \w \i \t \h \space \n \e \w \l \y \space \d \i \a \g \n \o \s \e \d " ..."]]

[:content [\C \a \n \a \d \a \' \s \space \c \u \r \r \e \n \t \space \\ \" \p \a \t \c \h \w \o \r \k \\ \" \space \s \y \s \t \e \m \space \o \f \space \p \r \e \s \c \r \i \p \t \i \o \n \space \d \r \u \g \space \c \o \v \e \r \a \g \e \space \i \s \space \p \u \s \h \i \n \g \space \u \p \space \c \o \s \t \s \, \space \c \r \e \a \t \e \s \space \m \a \s \s \i \v \e \space \c \o \n \f \u \s \i \o \n \space \a \n \d \space \r \e \s \u \l \t \s \space \i \n \space \s \i \g \n \i \f \i \c \a \n \t \space \f \i \n \a \n \c \i \a \l " ..."]]

People with HER2 positive metastatic breast cancer in Prince Edward Island (P.E.I.) will now be able to access a new treatment option through ...

The CADTH pan-Canadian Oncology Drug Review (pCODR) program is recruiting for membership on the pCODR Expert Review Committee. They are seeking ...

Janssen Inc. announced today that Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Imbruvica (ibrutinib) an oral, ...

The pCODR does not recommend the funding of aflibercept when used in combinaiton with an irinotecan and a fluoropyrimidine (FOLFIRI) ...